{"id":147716,"date":"2026-11-10T20:38:31","date_gmt":"2026-11-10T11:38:31","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4554-20261110-03_wp_financial_summary\/"},"modified":"2026-11-10T20:38:31","modified_gmt":"2026-11-10T11:38:31","slug":"4554-20261110-03_wp_financial_summary","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/","title":{"rendered":"Fuji Pharma Co., Ltd. Supplemental Materials for the Fiscal Year Ended September 2026"},"content":{"rendered":"<p>Published an overview of consolidated results for the fiscal year ended September 2026. Revenue was 59,250 hundred million yen (revised), gross profit margin declined to 39.0%, operating income increased year-over-year, and an impairment loss on available-for-sale securities of 2,000 hundred million yen was recorded as an extraordinary loss. By segment, women&#8217;s healthcare, biosimilars, and CMO continued to drive growth. The full-year forecast shows the revised projection and differences compared with the prior year.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4554","jir_company_name":"Fuji Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4554-20261110-03.pdf","jir_short_summary":"Published an overview of consolidated results for the fiscal year ended September 2026. Revenue was 59,250 hundred million yen (revised), gross profit margin declined to 39.0%, operating income increased year-over-year, and an impairment loss on available-for-sale securities of 2,000 hundred million yen was recorded as an extraordinary loss. By segment, women's healthcare, biosimilars, and CMO continued to drive growth. The full-year forecast shows the revised projection and differences compared with the prior year.","jir_summary":"### Overview of Results\nConsolidated results for the fiscal year ended September 2026 achieved revenue of 59,250 hundred million yen (compared with the revised forecast), gross profit of 24,321 hundred million yen, and operating income of 6,355 hundred million yen, all increasing year-over-year. Meanwhile, ordinary income was 6,176 hundred million yen and net income was 2,831 hundred million yen, showing slight declines. This was affected by an impairment loss on available-for-sale securities of 2,000 hundred million yen recorded as an extraordinary loss. EBITDA reached 10,562 hundred million yen, and gross profit margin declined to 39.0% against a backdrop of increased expenses including foreign exchange impacts. By segment, women's healthcare, biosimilars, and CMO continued to drive growth.\n\n### Medium- to Long-term Outlook and Strategy\nAll three growth strategies in the medium-term management plan (women's healthcare, biosimilars, and global CMO) are maintaining growth. In the segment revenue breakdown, expansion in women's healthcare and biosimilars continues. The launch status of new drugs and generics and the inclusion of drugs in reimbursement pricing are expected to affect future performance. The full-year forecast reflects the revised level, and attention should be paid to the impacts of foreign exchange and rising raw material costs.","jir_financial_highlights":"Revenue: 59,250 hundred million yen (Cumulative results for 26\/9 vs cumulative results for 25\/9 \/ Year-over-Year)\nGross Profit: 24,321 hundred million yen (Year-over-Year +38.5%)\nOperating Income: 6,355 hundred million yen (Year-over-Year +27.4%)\nOrdinary Income: 6,176 hundred million yen (Year-over-Year +38.5%)\nNet Income Attributable to Owners of Parent: 2,831 hundred million yen (Year-over-Year -5.6%)\nEBITDA: 10,562 hundred million yen (Year-over-Year +19.1%)\nImpairment Loss on Available-for-Sale Securities: 2,000 hundred million yen (Recorded)\nCapital Expenditures: 2,783 hundred million yen (Increase from prior period)","jir_category":"","jir_hashtags":"#FujiPharmaCoLtd, #Earnings, #WomensHealthcare, #Biosimilars, #CMO","jir_key_figures":"Revenue: 59,250 hundred million yen (revised forecast) Specified cumulative results\nOperating Income: 6,355 hundred million yen\nNet Income Attributable to Owners of Parent: 2,831 hundred million yen","jir_meta_title":"Fuji Pharma Co., Ltd. Supplemental Materials for FY 26\/9 | Revenue 59,250 hundred million yen; Revenue Up but Gross Margin Down","jir_meta_description":"Supplemental materials for Fuji Pharma Co., Ltd.'s fiscal year ended September 2026. Revenue was 59,250 hundred million yen, operating income was 6,355 hundred million yen, and an impairment loss on available-for-sale securities of 2,000 hundred million yen was recorded as an extraordinary loss. Growth was driven by women's healthcare, biosimilars, and CMO. The document summarizes outlook and progress on the medium-term plan.","jir_og_title":"Fuji Pharma Co., Ltd. Announces Supplemental Materials for FY 26\/9 Results","jir_og_description":"Summary of Fuji Pharma Co., Ltd.'s supplemental financial materials: revenue was 59,250 hundred million yen and profits increased while gross margin declined. Progress on the medium-term strategy and future risks are outlined.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{ \\\"type\\\": \\\"line\\\", \\\"data\\\": { \\\"labels\\\": [\\\"25\/9\\\",\\\"26\/9\\\"], \\\"datasets\\\": [{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[51638,62386]}] } }\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{ \\\"type\\\": \\\"line\\\", \\\"data\\\": { \\\"labels\\\": [\\\"25\/9\\\",\\\"26\/9\\\"], \\\"datasets\\\": [{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[4990,6355]}] } }\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Gross Margin Trend\", \"jir_chart_json_data\": \"{ \\\"type\\\": \\\"line\\\", \\\"data\\\": { \\\"labels\\\": [\\\"25\/9\\\",\\\"26\/9\\\"], \\\"datasets\\\": [{\\\"label\\\":\\\"Gross Margin\\\",\\\"data\\\":[40.2,39.0]}] } }\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue\", \"jir_chart_json_data\": \"{ \\\"type\\\": \\\"bar\\\", \\\"data\\\": { \\\"labels\\\": [\\\"Womens Healthcare\\\",\\\"Biosimilars\\\",\\\"CMO\\\",\\\"Others\\\"], \\\"datasets\\\": [{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[26734,5019,8975,21016]}] } }\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs Actual Comparison\", \"jir_chart_json_data\": \"{ \\\"type\\\": \\\"bar\\\", \\\"data\\\": { \\\"labels\\\": [\\\"25\/9\\\",\\\"26\/9\\\"], \\\"datasets\\\": [{\\\"label\\\":\\\"Actual\\\",\\\"data\\\":[51638,62386]},{\\\"label\\\":\\\"Revised Forecast\\\",\\\"data\\\":[59250,59250]}] } }\"}]","ir_related_company":17504,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-147716","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Fuji Pharma Co., Ltd. Supplemental Materials for the Fiscal Year Ended September 2026 - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/\",\"name\":\"Fuji Pharma Co., Ltd. Supplemental Materials for the Fiscal Year Ended September 2026 - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-10T11:38:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fuji Pharma Co., Ltd. Supplemental Materials for the Fiscal Year Ended September 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fuji Pharma Co., Ltd. Supplemental Materials for the Fiscal Year Ended September 2026 - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/","url":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/","name":"Fuji Pharma Co., Ltd. Supplemental Materials for the Fiscal Year Ended September 2026 - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-10T11:38:31+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4554\/ir\/4554-20261110-03_wp_financial_summary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Fuji Pharma Co., Ltd. Supplemental Materials for the Fiscal Year Ended September 2026"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"17504","title":"FUJI PHARMA CO LTD","ticker":"4554"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/147716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=147716"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/147716\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=147716"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=147716"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=147716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}